

MEDIA RELEASE

Cordlife expands its global footprint to Cambodia

- Cordlife has appointed IS Premium Lab as its distribution partner in Cambodia to provide genetic testing and non-invasive prenatal testing services.
- The Group now provides its full range of diagnostic products and services to six key Asian markets: Singapore, Hong Kong, India, the Philippines, Indonesia and Malaysia.
- The geographical expansion to Cambodia is a positive step forward for the Group's diagnostic services business, which has been growing steadily.

SINGAPORE, 22 FEBRUARY 2023 – Cordlife Group Limited (“**Cordlife**”, together with its subsidiaries, the “**Group**”), a Singapore Exchange mainboard listed company, is pleased to announce that its wholly-owned subsidiary Cordlife (Hong Kong) Ltd. (“**Cordlife Hong Kong**” or the “**Company**”) has entered into a distribution partnership with IS Premium Co. Ltd. (“**IS Premium**”) to provide genetic testing and non-invasive prenatal testing services in Cambodia.

Cambodia is one of the fastest-growing economies in the region, with an average annual GDP growth rate of 7.1% between 1994 and 2021.¹ As of 2022, the country's population is estimated to be 16.8 million, with an annual birth rate of 420,000. According to the World Bank, Cambodia's economy is thriving, and it is on track to attain upper middle-income status by 2030. This increase in disposable income and overall wealth is likely to translate into higher healthcare spending. Overall healthcare segment revenue in Cambodia is expected to grow at a rate of 28.84% per year (CAGR 2023-2027), providing an excellent opportunity for Cordlife to capitalise on and improve the well-being of mothers and children throughout the country.²

IS Premium is a reputable medical laboratory and diagnostic distribution player in Cambodia, offering 600 tests such as haematology, clinical biochemistry, sero-immunology, microbiology, molecular

¹ PWC: Cambodia's Infrastructure Market Update and Outlook, 21 Feb 2023

² Statista: Health Care – Cambodia, 21 Feb 2023



biology, tumour markers, and hereditary diseases, to over 300 medical partners. They are currently collaborating with Phnom Penh's top maternity hospitals, such as Orchid Koh Pich Hospital, Khema International and Sunrise Japan Hospital, to provide analysis for certain diagnostic tests.

“This is a great opportunity for Cordlife to expand the reach of our various products and services to new geographies,” said Ms Tan Poh Lan, Group CEO and Executive Director of Cordlife Group Limited. “Cordlife has invested in research and development over the last two years through Cordlife Hong Kong to create a variety of proprietary in-house tests in order to further develop the Company as the Group’s testing service hub. Cordlife Hong Kong will continue to broaden the Group’s footprint by expanding its distribution network to more untapped markets. We are confident that IS Premium will provide us with the right expertise and resources to avail our products and services throughout Cambodia, owing to their years of experience in this field.”

Among the tests that will be distributed by IS Premium are Cordlife carrier screening, bebegene® children genetic screening test, Cordlife talent genetic test, preimplantation genetic screening and MicroRNA-based endometrial receptivity analysis (“**MIRA**”) as well as non-invasive prenatal testing (“**NIPT**”) and Metascreen®, Cordlife’s non-invasive newborn metabolic screening which screens 106 inborn errors of metabolism. IS Premium will first make some of these services available in most of the women’s and paediatric clinics, as well as maternity hospitals in Phnom Penh, before expanding to other parts of the country.

End



ABOUT CORDLIFE GROUP LIMITED

Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, is a leading company dedicated to safeguarding the well-being of mother and child. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia. Cordlife operates Asia’s largest network of cord blood banks. With full stem cell banking facilities in six key markets, Cordlife is an industry leader in Singapore, Hong Kong, Indonesia and the Philippines, and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. In addition to cord blood, cord lining and cord tissue banking, Cordlife offers families a comprehensive suite of diagnostics services, including non-invasive prenatal testing, paediatric vision screening and newborn metabolic screening.

Two of Cordlife’s primary focus areas are providing reliable quality and being customer-centric. All of the Group’s facilities are accredited by the Association for the Advancement of Blood & Biotherapies (“AABB”), an organisation dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available and effective worldwide. Furthermore, Cordlife Singapore and Healthbaby Hong Kong are the only two private cord blood banks in Asia and five worldwide to be accredited by both AABB and the Foundation for the Accreditation of Cellular Therapy (“FACT”), another world-class accreditation body for cord blood banks worldwide. In the area of clinical diagnostics, Cordlife India and Healthbaby Hong Kong are both accredited by the College of American Pathologists (“CAP”). This makes Healthbaby Hong Kong the only private cord blood bank in the world to be accredited by three international standard-setting bodies, and Cordlife India is one of the only two medical laboratories in West Bengal to be holding accreditations from the National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and CAP. These quality achievements reinforce the Group’s commitment to providing reliable healthcare solutions through innovation and technological advancement. For more information, visit <http://cordlife.listedcompany.com>.

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Financial PR
4 Robinson Road #04-01
The House of Eden
Singapore 048543

CONTACT : Mr. Kamal Samuel / Ms. Urvija Diwan

OFFICE : (65) 6438 2990

EMAIL : kamal@financialpr.com.sg / urvija@financialpr.com.sg